Evidence map›Paper›PMID 29535432›Full record

ArticleLeukemia2018

Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.

Anne Buffière, Théo Accogli, Laetitia Saint-Paul, Géraldine Lucchi, Benjamin Uzan, Paola Ballerini, Jean-Noël Bastie, Laurent Delva, Françoise Pflumio, Ronan Quéré

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Anne BuffièreUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France.
Théo AccogliUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France.
Laetitia Saint-PaulUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France.
Géraldine LucchiPlateforme de Protéomique, Université Bourgogne Franche-Comté, Dijon, France.
Benjamin UzanUMR967, Inserm / CEA / Université Paris 7 / Université Paris 11, Fontenay-aux-Roses, France.
Paola BalleriniAssistance Publique-Hôpitaux de Paris, Laboratoire d'Hématologie, Hôpital Trousseau, Paris, France.
Jean-Noël BastieUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France.
Laurent DelvaUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France.
Françoise PflumioUMR967, Inserm / CEA / Université Paris 7 / Université Paris 11, Fontenay-aux-Roses, France.
Ronan QuéréUMR1231, Inserm / Université Bourgogne Franche-Comté, Dijon, France. ronan.quere@inserm.fr.
Université Bourgogne Franche-Comté · FRCentre de recherche Translationnelle en Médecine moléculaire · FRInserm · FRCEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRHôpital Armand-Trousseau · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsBenzodioxolesCell Line, TumorDisease Models, AnimalHumansLymphocyte Specific Protein Tyrosine Kinase p56(lck)Membrane MicrodomainsMembrane Potential, MitochondrialMiceNeoplastic Stem CellsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaQuinazolinesReactive Oxygen SpeciesXenograft Model Antitumor AssaysAntineoplastic AgentsBenzodioxolesLymphocyte Specific Protein Tyrosine Kinase p56(lck)QuinazolinesReactive Oxygen Speciessaracatinib

Identifiers

PMID29535432
OpenAlexW2792013220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.